Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

BACKGROUND: : Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0.84, 95% CI 0.73–0.98, P = 0.022]. Post hoc analyses of RAISE patient data examined the association of RAS/RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, T, Portnoy, D C, Obermannová, R, Bodoky, G, Prausová, J, Garcia-Carbonero, R, Ciuleanu, T, García-Alfonso, P, Cohn, A L, Van Cutsem, E, Yamazaki, K, Lonardi, S, Muro, K, Kim, T W, Yamaguchi, K, Grothey, A, O’Connor, J, Taieb, J, Wijayawardana, S R, Hozak, R R, Nasroulah, F, Tabernero, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336001/
https://www.ncbi.nlm.nih.gov/pubmed/30339194
http://dx.doi.org/10.1093/annonc/mdy461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336001/
https://www.ncbi.nlm.nih.gov/pubmed/30339194
http://dx.doi.org/10.1093/annonc/mdy461

Ejemplares similares